Clinical Trials Browser

Phase 3 × Urinary Bladder Neoplasms × Docetaxel × Clear all

NCT07419295 2026-05-22

TroFuse-031

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT04579224 2026-05-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Phase 3 Completed

608 enrolled 22 charts 1 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02426125 2023-08-21

RANGE

Phase 3 Completed

530 enrolled 22 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

NCT02256436 2021-09-20

MK-3475-045

Phase 3 Completed

542 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT02302807 2019-08-01

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Phase 3 Completed

931 enrolled 21 charts

Urinary Bladder Neoplasms

NCT00041171 2016-07-12

Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

Phase 3 Withdrawn

BreastCNSGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma